Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 2,795 matching trials from the live ClinicalTrials.gov search.
Recruiting No phase listed Observational

Abbott Structural Heart Device Registry

NCT06590467
Conditions
Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions
Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
13
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more
Conditions
Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Interventions
IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
Device · Drug
Lead sponsor
IMGT Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Boston, Massachusetts • San Antonio, Texas • Charlottesville, Virginia
Conditions
HIV Infections
Interventions
HIV LFn-p24
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Electronic Cigarette Use, Cigarette Use, Electronic, Tobacco Use, Tobacco Smoking
Interventions
Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS, Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS, Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS, Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette, Tobacco/Nicotine Abstention, Usual Brand of cigarettes
Other
Lead sponsor
Juul Labs, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Rogers, Arkansas • St Louis, Missouri + 2 more
Conditions
Smoking Cessation, Cervical Cancer, High Grade Cervical Dysplasia
Interventions
Smoking Cessation treatment delivered by Tobacco Free Florida Quitline, Nicotine patch, Nicotine Lozenge, Motivation and Problem Solving (MAPS) intervention
Behavioral · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Advanced Malignancies
Interventions
CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod, poly-ICLC
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
New Haven, Connecticut • Miami Beach, Florida • Detroit, Michigan + 3 more
Conditions
Knee Osteoarthritis
Interventions
Orthovisc, DonJoy HA lite knee brace, Orthovisc injections and DonJoy HA lite knee brace
Other · Device
Lead sponsor
OAD Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Warrenville, Illinois
Conditions
Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pain questionnaires
Behavioral
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
279
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 181 more
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Conditions
Laceration of Skin, Anxiety, Discharge Time
Interventions
Intranasal Midazolam, Intranasal Dexmedetomidine, Intranasal Ketamine
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 5 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Obesity or Overweight, Cardiovascular Disease
Interventions
Petrelintide, Placebo
Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Anniston, Alabama • Los Angeles, California • San Carlos, California + 3 more
Conditions
Asthma
Interventions
MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more
Conditions
Advanced Ovarian Cancer, Triple Negative Breast Cancer
Interventions
Atezolizumab, RO6870810
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
Conditions
Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic
Interventions
Ofatumumab, Bendamustine
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Tuscon, Arizona • Aurora, Colorado • Fort Myers, Florida + 3 more
Conditions
Healthcare Facility Environment - Imaging
Interventions
Light perception, Sound perception, Smell perception, Vibration perception, Voice activation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers

INSIGHT, A Comprehensive, Multidisciplinary Brain Training System

NCT02780739
Conditions
Cognitive Ability, General
Interventions
Cognitive Training - 48 sessions, Fitness, Active Control, active tDCS, sham tDCS, Cognitive Training - 20 sessions
Behavioral · Device
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 44 Years
Enrollment
521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Urbana, Illinois
Terminated Phase 4 Interventional Results available

LOSS- Louisiana Obese Subjects Study

NCT00115063
Conditions
Obesity
Interventions
group sessions, sibutramine, orlistat, diethylpropion, Low Calorie Diet, Health One, Intensive Medical Combination Therapy for Obesity, Control Condition
Behavioral · Drug · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
20 Years to 60 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma
Interventions
Number of Participants with massive blood transfusion
Procedure
Lead sponsor
Zeliha Alicikus
Government
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Jacksonville, Florida
Conditions
Adolescent, Depression, Substance Use Disorders
Interventions
Adolescent Coping With Depression/Functional Family Therapy
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Eugene, Oregon
Completed Not applicable Interventional Accepts healthy volunteers Results available

Don't Throw Your Heart Away: Clinician Study 3

NCT04455893
Conditions
Cardiac Transplant Disorder
Interventions
Stratified Transplant Survival
Other
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Dato-DXd, Osimertinib, Pemetrexed, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Fayetteville, Arkansas • Fountain Valley, California • San Diego, California + 6 more
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 49 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
121
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Mental Health in School-age Children Through the Kids' Empowerment Program (KEP)

NCT06354907
Conditions
Child Mental Disorder
Interventions
The Kids' Empowerment Program
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan